FLGT250117C15000
- 6.35
- 0.000.00%
Fulgent Genetics Newsroom
Following a 25% Decline Over Last Year, Recent Gains May Please Fulgent Genetics, Inc. (NASDAQ:FLGT) Institutional Owners
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Fulgent Genetics Analyst Ratings
Piper Sandler Maintains Fulgent Genetics(FLGT.US) With Hold Rating, Cuts Target Price to $22
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript Summary
Express News | Fulgent Genetics Inc : Piper Sandler Cuts Target Price to $22 From $26
Companies Like Fulgent Genetics (NASDAQ:FLGT) Are In A Position To Invest In Growth
Fulgent Genetics Third Quarter 2024 Earnings: EPS Misses Expectations
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics | 10-Q: Q3 2024 Earnings Report
Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est
Fulgent Genetics | 8-K: Fulgent Reports Third Quarter 2024 Financial Results
Fulgent Genetics Non-GAAP EPS of $0.31 Beats by $0.46, Revenue of $71.74M In-line
Express News | Fulgent Genetics Inc Outlook FY 2024 Adj EPS $0.33
Express News | Fulgent Genetics Inc: Reiterates Full Year 2024 Core Revenue Guidance of $280 Mln
Fulgent Genetics Sees End-2024 Cash, Equivalents, Marketable Securities About $800M >FLGT
Express News | Fulgent Genetics Q3 Operating Expenses USD 43.85 Million
Fulgent Reports Third Quarter 2024 Financial Results
Fulgent Genetics 3Q Loss $14.6M >FLGT